On June 10, 2025, Indaptus Therapeutics, Inc. held its Annual Meeting where 8,386,348 shares were represented, electing three directors and approving the appointment of Haskell & White LLP as auditors, with a proposal for a reverse stock split between 1-for-5 and 1-for-28 also receiving approval.